MedTrace Logo

LBBAP Data Collection Registry

NCT05887323 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 221

Last updated 2024-10-08

Study results available
· View outcomes & findings →

Summary

The purpose of this registry is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients already implanted with the Tendril STS 2088 lead.

Conditions

  • Bradycardia
  • Sinus Node Dysfunction
  • Heart Block
  • Syncope
  • Cardiomyopathies
  • Heart Failure

Interventions

DEVICE

Implantation of the Tendril 2088 lead in the LBBA

Conduction system pacing is achieved by delivering a pacing stimulus to the Left Bundle Branch area of the heart with Abbott's Tendril 2088 lead.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Kwangdeok Lee · Abbott

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2023-07-11
Completion
2023-07-11
FDA Device
Yes

Countries

  • United States
  • France
  • India
  • Italy
  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05887323 on ClinicalTrials.gov